Uncovering Potential: Kura Oncology's Earnings Preview
Express News | Kura Oncology Announces First Patients Dosed in Phase 1 Combination Trial of Ziftomenib for the Treatment of Advanced Gist
Kura Oncology Announces First Patients Dosed in Phase 1 Combination Trial of Ziftomenib for the Treatment of Advanced GIST
Earnings Preview: KURA to Report Financial Results Post-market on May 01
Kura Oncology to Report First Quarter 2025 Financial Results
LifeSci Capital Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $24
H.C. Wainwright Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $40
Strategic Advancements and Early NDA Submission Drive Buy Rating for Kura Oncology
Express News | Kura Oncology Inc: Expects to Receive Notification From FDA on This Preliminary Evaluation in Q2 of 2025
Express News | Kura Oncology and Kyowa Kirin Announce Submission of New Drug Application for Ziftomenib to FDA
Excelerate Energy, MediaAlpha And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Kura Oncology to Participate in Stifel Targeted Oncology Forum
Kura Oncology Announces Preclinical Data for KO-2806 Selected for Oral Presentation at the 2025 AACR Annual Meeting
Express News | Kura Oncology Announces Preclinical Data for Ko-2806 Selected for Oral Presentation at the 2025 AACR Annual Meeting
Express News | Kura Oncology Grants 190,000 Stock Options To Six New Employees As Inducement Awards
Press Release: Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Kura Oncology Price Target Cut to $14.00/Share From $27.00 by UBS
UBS Maintains Kura Oncology(KURA.US) With Buy Rating, Cuts Target Price to $14
Analysts Are Bullish on Top Healthcare Stocks: HCA Healthcare (HCA), Kura Oncology (KURA)
Kura Oncology's Financial Future at Risk: Dependency on Kyowa Kirin for Ziftomenib Development Raises Concerns